Ironwood Pharmaceuticals Inc Total Liabilities
Ironwood Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has total liabilities worth $446.97 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Ironwood Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ironwood Pharmaceuticals Inc (2007–2025)
Total liabilities of Ironwood Pharmaceuticals Inc from 2007 to 2025. This chart illustrates how Ironwood Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Ironwood Pharmaceuticals Inc (IRWD) investment intensity to see how much of total assets are deployed in long-term investments.
Ironwood Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mengtian Home Group Inc.
SHG:603216
|
China | CN¥384.28 Million |
|
Nano Nuclear Energy Inc. Common Stock
NASDAQ:NNE
|
USA | $6.09 Million |
|
Haier Smart Home Co Ltd
F:690D
|
Germany | €165.78 Billion |
|
Merida Industry Co Ltd
TW:9914
|
Taiwan | NT$15.38 Billion |
|
Guangdong Enpack Packaging Co Ltd
SHE:002846
|
China | CN¥2.37 Billion |
|
Turkiye Sinai Kalkinma Bankasi AS
IS:TSKB
|
Turkey | TL251.26 Billion |
|
JuneYao Dairy Co Ltd
SHG:605388
|
China | CN¥352.63 Million |
|
Mesa Laboratories Inc
NASDAQ:MLAB
|
USA | $248.16 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Ironwood Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IRWD current and non-current assets.
Liquidity & Leverage Metrics
Ironwood Pharmaceuticals Inc Total Liabilities Ratios Explained
Ironwood Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ironwood Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ironwood Pharmaceuticals Inc (2007–2025)
The table below shows the annual total liabilities of Ironwood Pharmaceuticals Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $658.74 Million | +1.00% |
| 2024-12-31 | $652.24 Million | -20.20% |
| 2023-12-31 | $817.37 Million | +82.39% |
| 2022-12-31 | $448.14 Million | -13.99% |
| 2021-12-31 | $521.02 Million | +4.92% |
| 2020-12-31 | $496.60 Million | +0.12% |
| 2019-12-31 | $496.00 Million | -6.14% |
| 2018-12-31 | $528.42 Million | -11.31% |
| 2017-12-31 | $595.83 Million | -7.35% |
| 2016-12-31 | $643.11 Million | +22.73% |
| 2015-12-31 | $524.00 Million | +113.91% |
| 2014-12-31 | $244.96 Million | +1.75% |
| 2013-12-31 | $240.74 Million | +180.40% |
| 2012-12-31 | $85.86 Million | -13.38% |
| 2011-12-31 | $99.12 Million | -30.10% |
| 2010-12-31 | $141.81 Million | -69.22% |
| 2009-12-31 | $460.79 Million | +24.16% |
| 2008-12-31 | $371.13 Million | +18.09% |
| 2007-12-31 | $314.28 Million | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more